CytomX Therapeutics Inc. (NASDAQ:CTMX) shares rose 5.1% during mid-day trading on Tuesday . The stock traded as high as $11.89 and last traded at $11.71, with a volume of 61,561 shares. The stock had previously closed at $11.14.

CTMX has been the subject of several recent research reports. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of CytomX Therapeutics in a report on Tuesday, May 10th. Zacks Investment Research raised shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 10th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. CytomX Therapeutics currently has an average rating of “Buy” and an average target price of $19.00.

The stock’s market capitalization is $428.92 million. The firm’s 50-day moving average price is $10.66 and its 200-day moving average price is $11.61.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.39) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.02. Equities analysts expect that CytomX Therapeutics Inc. will post ($1.59) EPS for the current fiscal year.

In related news, Director Ix L.P. Canaan sold 59,621 shares of the stock in a transaction on Friday, June 3rd. The shares were sold at an average price of $10.80, for a total value of $643,906.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Timothy M. Shannon sold 48,427 shares of the stock in a transaction on Friday, June 10th. The shares were sold at an average price of $10.07, for a total transaction of $487,659.89. Following the completion of the transaction, the director now directly owns 134 shares in the company, valued at $1,349.38. The disclosure for this sale can be found here.

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.